IMW 2019 | Myeloma: why PROMISE?
Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, outlines the aims, methods and results of the PROMISE study (NCT03689595), at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
Get great new content delivered to your inboxSign up
Exciting results from CARTITUDE-1: anti-BCMA CAR-T for MM
ERd in the treatment of newly diagnosed MM
MUK Seven biomarker trial: prognostic molecular stratification in R/R MM
From bb2121 to bb21217: does bb007 improve efficacy in MM?
Molecular therapy stratification for high-risk MM: MUK Nine b OPTIMUM
More from Annie Cowan